These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 30054313)
21. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers. Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685 [TBL] [Abstract][Full Text] [Related]
22. The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases. Tsafaras G; Baekelandt V Neurobiol Dis; 2022 Oct; 172():105806. PubMed ID: 35781002 [TBL] [Abstract][Full Text] [Related]
23. First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation. Puschmann A; Englund E; Ross OA; Vilariño-Güell C; Lincoln SJ; Kachergus JM; Cobb SA; Törnqvist AL; Rehncrona S; Widner H; Wszolek ZK; Farrer MJ; Nilsson C Parkinsonism Relat Disord; 2012 May; 18(4):332-8. PubMed ID: 22154298 [TBL] [Abstract][Full Text] [Related]
24. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. Martí-Massó JF; Ruiz-Martínez J; Bolaño MJ; Ruiz I; Gorostidi A; Moreno F; Ferrer I; López de Munain A Mov Disord; 2009 Oct; 24(13):1998-2001. PubMed ID: 19735093 [TBL] [Abstract][Full Text] [Related]
25. The LRRK2-macroautophagy axis and its relevance to Parkinson's disease. Manzoni C Biochem Soc Trans; 2017 Feb; 45(1):155-162. PubMed ID: 28202669 [TBL] [Abstract][Full Text] [Related]
26. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease. Monfrini E; Di Fonzo A Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276 [TBL] [Abstract][Full Text] [Related]
27. LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease. Lee H; James WS; Cowley SA Biochem Soc Trans; 2017 Feb; 45(1):131-139. PubMed ID: 28202666 [TBL] [Abstract][Full Text] [Related]
28. New Frontiers in Parkinson's Disease: From Genetics to the Clinic. Shihabuddin LS; Brundin P; Greenamyre JT; Stephenson D; Sardi SP J Neurosci; 2018 Oct; 38(44):9375-9382. PubMed ID: 30381429 [TBL] [Abstract][Full Text] [Related]
29. Defects in trafficking bridge Parkinson's disease pathology and genetics. Abeliovich A; Gitler AD Nature; 2016 Nov; 539(7628):207-216. PubMed ID: 27830778 [TBL] [Abstract][Full Text] [Related]
30. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations. Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983 [TBL] [Abstract][Full Text] [Related]
31. Genetics of Parkinson's disease: a review of SNCA and LRRK2. Konno T; Siuda J; Wszolek ZK Wiad Lek; 2016; 69(3 Pt 1):328-32. PubMed ID: 27486710 [TBL] [Abstract][Full Text] [Related]
32. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease. Bergareche A; Rodríguez-Oroz MC; Estanga A; Gorostidi A; López de Munain A; Castillo-Triviño T; Ruiz-Martínez J; Mondragón E; Gaig C; Lomeña F; Sarasqueta C; Tolosa E; Martí-Massó JF Mov Disord; 2016 Mar; 31(3):335-43. PubMed ID: 26686514 [TBL] [Abstract][Full Text] [Related]
33. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161 [TBL] [Abstract][Full Text] [Related]
34. In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology. Vermilyea SC; Emborg ME Stem Cells Dev; 2018 Jul; 27(14):960-967. PubMed ID: 29402177 [TBL] [Abstract][Full Text] [Related]
35. Biochemical and pathological characterization of Lrrk2. Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584 [TBL] [Abstract][Full Text] [Related]
36. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Gomez A; Ferrer I Acta Neuropathol; 2010 Aug; 120(2):155-67. PubMed ID: 20232069 [TBL] [Abstract][Full Text] [Related]
37. Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus. Tatura R; Kraus T; Giese A; Arzberger T; Buchholz M; Höglinger G; Müller U Parkinsonism Relat Disord; 2016 Dec; 33():115-121. PubMed ID: 27717584 [TBL] [Abstract][Full Text] [Related]